tbuckley/cabot-search huggingface dataset:
53091 Demodicosis and ivermectin-associated Mazzotti-like reactions in hematopoietic cell transplant recipients: a case series
Authors: Jennifer Strong, Alexandra Firek, Dennis D. Hickstein, Steven Pavletic, Richard Childs, Dimana Dimitrova, Jennifer A. Kanakry, Christopher G. Kanakry, Edward W. Cowen, Leslie Castelo-Soccio, Isaac Brownell
Journal: Journal of the American Academy of Dermatology (2024)
53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis
Authors: Eric Simpson, Mark Boguniewicz, Lawrence Eichenfield, Mercedes E. Gonzales, Adelaide A. Hebert, Vimal H. Prajapati, Melinda Gooderham, David Krupa, David H. Chu, Robert C. Higham, David R. Berk
Journal: Journal of the American Academy of Dermatology (2024)
50564 Novel Natural Moisturizing Factor and Lipid-Containing Face Cream Induces Aquaporin-3 and Filaggrin Expression Associated with Barrier Improvements and Sustained Clinical Hydration in Extra-Dry Skin
Authors: Katrina T. Bernhardt, Erin Zaleski, Wen-Hwa Li, Ramine Parsa, Dara Miller, Adegboyega Adenaike, Julie M. Bianchini
Journal: Journal of the American Academy of Dermatology (2024)
51569 Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies
Authors: Joseph F. Merola, Diamant Thaçi, Barbara Ink, Rajan Bajracharya, Jérémy Lambert, Jason Coarse, Alice B. Gottlieb
Journal: Journal of the American Academy of Dermatology (2024)
54537 The Risk of Infections with Janus Kinase Inhibitor Treatment for Atopic Dermatitis: A Systematic Review and Meta-Analysis
Authors: Muskaan Sachdeva, Nawar Tarafdar, Natnaiel Dubale, Ciaran Smythe, Yuliya Lytvyn, Khalad Maliyar, Jorge Georgakopoulos, Asfandyar Mufti, Jensen Yeung
Journal: Journal of the American Academy of Dermatology (2024)
53577 Cutaneous manifestations, presenting symptoms, and tumor prevalence by race and sex in Neurofibromatosis 1 patients: a retrospective cohort study at an academic institution, NY, NY
Authors: Samantha Jo Albucker, Kaya Curtis, Victoria De Barros, Yuging Qiu, Shari R. Lipner
Journal: Journal of the American Academy of Dermatology (2024)
52654 Reaching high treatment goals is linked with a high quality of life in psoriasis patients; 1-year data from the German VALUE study
Authors: Petra Staubach, Thomas Stavermann, Rachel Sommer, Matthias Hoffmann, Dariusch Mortazawi, Marius Schild, Kristina Lohmann, Uwe Gieler, Diamant Thaçi
Journal: Journal of the American Academy of Dermatology (2024)
54567 Skin Cancer Among People with Intellectual Disabilities: a Scoping Review and Recommendations for More Effective Detection and Prevention
Authors: Brigit A. Lapolla, Emily R. Gordon, Celine M. Schreidah, Lauren M. Fahmy, Oluwaseyi Adeuyan, Caroline Chen, Larisa J. Geskin
Journal: Journal of the American Academy of Dermatology (2024)
54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
Authors: Brett King, Natasha A. Mesinkovska, Arash Mostaghimi, Colleen Hamilton, James Cassella
Journal: Journal of the American Academy of Dermatology (2024)

Introduction: Deuruxolitinib, a selective JAK1/JAK2 inhibitor, demonstrated significant hair regrowth in patients with alopecia areata (AA) in the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials. Here, pooled safety measures from these two trials are reported.
51282 Evaluating the Utility of a Novel Cosmeceuticals Educational Pamphlet in Optimizing Clinic Workflow, Knowledge, and Comfort Among Dermatology Providers
Authors: Sheetal Sethupathi, Kavita Darji, Sumvrudhi Chariyamane, Krithika Narayana Kumanan, Saniya Shaikh, Jennifer Fehlman
Journal: Journal of the American Academy of Dermatology (2024)
52472 Deconstructing Trends in the Equity of Teledermatology Use and Outcomes Among Acne Patients on Isotretinoin During the COVID-19 Pandemic: A Single-Center Retrospective Comparative Analysis
Authors: Courtney Smith, Courtney Smith, Diana Wang, Deeti Pithadia, Marcia Hogeling, Carol Cheng
Journal: Journal of the American Academy of Dermatology (2024)
52246 Application of the Deep learning-based automated scoring system to predict eyelid Monopolar Radiofrequency treatment outcome: A Retrospective, Multicenter, Preliminary study
Authors: DongHye Suh, Hyun Joo Kim, HeongSeob Kim, SangJun Lee, InYong Kim, ByungChul Jang, Hei Sung Kim
Journal: Journal of the American Academy of Dermatology (2024)
52808 Guselkumab improves perceived stigmatization in moderate-to-severe psoriasis patients, including obese patients and patients with short disease duration: Results from the real-life G-EPOSS study until Week 76
Authors: Sascha Gerdes, Sebastian Zimmer, Andreas Schwinn, Rolf Ostendorf, Simmy Jacobsen, Judita Makuc, Nina Trenkler, Juliane Behrens, Sarah Tabori, Dariusch Mortazawi
Journal: Journal of the American Academy of Dermatology (2024)

Introduction: Psoriasis patients suffer from both physical disease burden and perceived stigmatization1,2, which represents a component of the psoriasis action plan of the World Health Organization (WHO)3. G-EPOSS, a prospective, German multicenter study takes a holistic view of patientś well-being, including perceived stigmatization, in addition to assessing the effectiveness of guselkumab in patients with moderate- to- severe psoriasis in routine clinical practice.
52574 Safety and efficacy of selective TYK2/JAK1 inhibitor, TLL-018, in moderate-to-severe plaque psoriasis
Authors: Min Zheng, Xiaoyong Man, Jiaqi Chen, Wenhao Yin, Ping Wang, Xiaowei Shi, Tiechi Lei, Zhiming Li, Meng Pan, Yuling Shi, Yuzhen Li
Journal: Journal of the American Academy of Dermatology (2024)
51125 PATIENT EXIT INTERVIEWS ILLUSTRATE BENEFIT OF TRIFAROTENE ON ACNE-INDUCED PIGMENTARY PROBLEMS
Authors: Andrew Alexis, James Del Rosso, Seth Forman, Antonio Calatayud, John Browning, Vivian Laquer, J.P. York, Rajeev Chavda, Sunil Dhawan, Angela Moore, Linda Stein-Gold
Journal: Journal of the American Academy of Dermatology (2024)
54309 A multicenter, intra-individual (left-right arm), randomized-controlled trial evaluating the safety and efficacy of using a dermocosmetic emollient versus a topical antimicrobial as adjunctive therapies for post-procedural wounds in dermatology
Authors: Nour Dayeh, Charles Lynde, Anneke Andiersen
Journal: Journal of the American Academy of Dermatology (2024)
51907 VISIBLE: Guselkumab Provides Significant Improvements in Health-related Quality of Life in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis
Authors: Jennifer Soung, Olivia Choi, Theodore Alkousakis, Mona Shahriari, Neelam Vashi, Daphne Chan, Katelyn Rowland, Laura Park-Wyllie, Jenny Jeyarajah, Andrew Alexis, Susan Taylor
Journal: Journal of the American Academy of Dermatology (2024)
51348 Low occurrence of predefined safety events across six randomized clinical trials of spesolimab in dermatologic conditions
Authors: Kenneth Gordon, Kilian Eyerich, Milan J. Anadkat, Siew Eng Choon, Boni Elewski, Jonathan N. Barker, Arash Mostaghimi, Ming Tang, Thomas Haeufel, Christian Thoma, Diamant Thaçi
Journal: Journal of the American Academy of Dermatology (2024)

In the randomized, placebo-controlled Effisayil 2 trial, the anti-interleukin (IL)-36 receptor antibody spesolimab demonstrated a reassuring safety profile when given over 48 weeks for flare prevention in patients with generalized pustular psoriasis (GPP). Nevertheless, given its novel mechanistic approach, it is important to characterize events relating to IL-36 inhibition with spesolimab as well as those of potential relevance to an intravenously/subcutaneously administered biologic. In this analysis, rates of such predefined events – severe/serious/opportunistic infections, potential hypersensitivity reactions, peripheral neuropathies, and malignant tumors – were examined using available data from six randomized trials of spesolimab across various dermatologic conditions. Events reported in patients receiving spesolimab at various doses and schedules in two trials in GPP, two in palmoplantar pustulosis (PPP), one in atopic dermatitis (AD), and one in hidradenitis suppurativa (HS) were included (total n=345 for spesolimab and 145 for placebo). Exposure to spesolimab was: GPP, 244.3; PPP, 327.8; AD, 40.0; and HS, 45.7 patient-years, respectively. Rates of severe/serious/opportunistic infections were low with spesolimab (3.2% in one GPP trial; otherwise, 0% vs. 0% with placebo), and the incidences of hypersensitivity reactions were similar for spesolimab (7.7–33.3%) and placebo (5.6–44.4%) across trials. There was one report of peripheral neuropathy with spesolimab in a PPP trial (incidence 0–0.9% across trials) versus two (one GPP, one PPP) with placebo (0–3.3%), and one malignancy with spesolimab in GPP (0–1.1% across trials) versus one with placebo in PPP (0–2.3%). These results support the favorable safety profile of spesolimab seen in Effisayil 2.
52344 Clinical Manifestations of Cutaneous Polyarteritis Nodosa: A Multicenter Cohort of 30 Patients
Authors: Nikki Zangenah, Bina Kassamali, Kylee Kus, Jacqueline Maher, Ali Asghar Kassamali, Daniel Mazori, Gabriela Cobos
Journal: Journal of the American Academy of Dermatology (2024)
51453 Gender affirming laser hair removal (LHR) impact on patient quality of life (QoL) and gender dysphoria
Authors: Reese Imhof, Christeebella Akpala, Hannah Haberecht, Jacob Reinhart, Caroline Davidge-Pitts, Hafsa Cantwell, Julio Sartori Valinotti
Journal: Journal of the American Academy of Dermatology (2024)

Introduction: LHR is as an essential part of the gender transition process,(1-3) but there is limited data on the impact of LHR on patient QoL and gender dysphoria.(4)
53464 Wait Times for Dermatology Appointments in Puerto Rico
Authors: Lillian Rivera-Rivera, Reina Gonzalez, Maria Vazquez-machado, Chavely Calderon, Maria Limardo, Myrta Rivera, Jashira Babilonia, Andrea Becemberg, Lorna Torres, Nestor Sanchez
Journal: Journal of the American Academy of Dermatology (2024)
51726 Evaluating the efficacy of oral alitretinoin in alopecia areata
Authors: Jinsu Lee, Jun-Oh Shin, Dongyoung Rho, Yeona Kim, Sang-Hyeon Won, Jungsoo Lee, Kihyuk Shin, Hoon-Soo Kim, Hyunchang Ko, Byungsoo Kim, Moon-Bum Kim
Journal: Journal of the American Academy of Dermatology (2024)
New strategies in soft tissue sarcoma treatment
Authors: Mariella Spalato-Ceruso, Nathan El Ghazzi, Antoine Italiano
Journal: Journal of Hematology & Oncology (2024)

Soft tissue sarcomas (STS) have long been a formidable challenge in oncology, partly because of their rarity and diversity, which complicates large-scale studies and slows the advent of new treatments. Traditionally anchored by anthracycline-based chemotherapy, the landscape of STS treatment hasn't shifted dramatically in the past twenty years. However, recent strides in research are starting to paint a more hopeful picture. Leveraging advanced molecular profiling, researchers are now tailoring treatments to the unique genetic makeup of tumors, with targeted therapies showing promise. Innovations such as NTRK inhibitors for NTRK-rearranged sarcomas and gamma-secretase inhibitors for desmoid tumors are changing clinical practices. The rise of immunotherapy, including novel agents like LAG-3 inhibitors and bifunctional proteins that target both TGF-β and PD-L1, offers new avenues for treatment, particularly when combined with traditional therapies like chemotherapy. Meanwhile, the approval of epigenetic treatments for specific sarcoma subtypes heralds a new wave of strategy based on histological specificity, which could lead to more personalized and effective care. While challenges remain, the field of STS treatment is evolving, driven by a deeper understanding of the disease's biological underpinnings and a commitment to innovative research approaches.
52633 The effects of temperature on indirect immunofluorescence testing for pemphigus and bullous pemphigoid
Authors: Sumruay Pinkaew, Kanokvalai Kulthanan, Papapit Tuchinda, Leena Chularojanamontri, Bawonpak Pongkittilar, Panyapat Buranaporn, Chuda Rujitharanawong
Journal: Journal of the American Academy of Dermatology (2024)
53803 Early and Sustained Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Participants with Moderate-to-Severe Scaling or Plaque Elevation
Authors: Linda Stein Gold, Emil Tanghetti, Edward Lain, Andrea Murina, Abby Jacobson
Journal: Journal of the American Academy of Dermatology (2024)
53510 Work and Productivity Impairment in Patients with Prurigo Nodularis: Results from the PN – paTient Reported burden of sicKness (PN-TREK) Study
Authors: Shawn G. Kwatra, Min Yang, Bruno Martins, Jingyi Liu, Joseph Zahn, Bengisu Ozarslan, Donia Bahloul, Ryan B. Thomas
Journal: Journal of the American Academy of Dermatology (2024)
53711 Guselkumab induction therapy is effective, safe and long lasting in mild psoriasis patients, results from a randomized, placebo-controlled exploratory trial
Authors: Robert Rissmann, Jannik Rousel, Menthe Bergmans, Laura van der Meulen, Marieke de Kam, Joke Bouwstra, Marieke Seyger, Juul van den Reek, Naomi Klarenbeek, Tessa Niemeyer-van der Kolk, Martijn van Doorn
Journal: Journal of the American Academy of Dermatology (2024)
54827 Prognostic value of SLC22A4, ELAC2, and KIF4B in metastatic melanoma: A weighted correlation network analysis of 53 peripheral blood mononuclear cell samples
Authors: Michael Diaz, Nicole Natarelli, Mahtab Forouzandeh, Majorie Montanez-Wiscovich
Journal: Journal of the American Academy of Dermatology (2024)
52179 Objective assessment of skin laxity Improvement after Monopolar Radiofrequency treatment: Histological results, Elasticity and Sebum Analysis
Authors: Hwa Jung Ryu, Dong Hye Suh, Hyun Joo Kim, Sang Jun Lee, Heong Seob Kim, Kye Yong Song, Ju Young Jo
Journal: Journal of the American Academy of Dermatology (2024)
52445 Comparison of infection rate between sterile and non-sterile gloves during Mohs Micrographic surgery: a systematic review and meta analysis
Authors: Rafaela de Moraes Souza, Rubiana Sarto, Lívia Figueiredo Pereira, Yasmin Luz Lima de Mesquita, Regina Chahine Chater, Izadora Lapenda, Luana Moury Fernandes Sanchez, Pedro Herranz
Journal: Journal of the American Academy of Dermatology (2024)
52667 Tildrakizumab improves sleep quality, quality of life and work productivity in patients with moderate-to-severe plaque psoriasis in conditions close to real clinical practice
Authors: Antonio Costanzo, Aldo Cuccia, Esteban Daudén, Gabriella Fabbrocini, Raquel Rivera-Diaz, Kristian Gaarn Du Jardin, Ismail Kasujee, Lluís Puig, José Manuel Carrascosa
Journal: Journal of the American Academy of Dermatology (2024)
52528 LONG LASTING HYDRATION AND SENSORIAL PROPERTIES OF A BODY MOISTURIZER CONTAINING ASCORBYL GLUCOSIDE, SQUALANE AND GLYCERINE IN AN ULTRALIGTH FLUID LOTION TECHNOLOGY
Authors: Fernanda Beltrao, Ana Lucia Coutinho, Raphael Pinheiro
Journal: Journal of the American Academy of Dermatology (2024)

Introduction:: Stratum corneum moisturization is the main parameter used to assess the efficacy of a moisturizer. In this analysis, the most commonly used methods are corneometry and transepidermal water loss measurement. A cosmetic treatment for xeroderma should re-establish the degree of moisturization by preserving and increasing its water content and reducing evaporation. A body moisturizer should associate efficacy with good sensorial characteristics, otherwise it could be a negative factor in adherence to treatment.
52891 Preliminary Evaluation of the Efficacy and Safety of Leukocyte-Poor Platelet-Rich Plasma in the Treatment of Melasma in Asian Patients
Authors: Panyapat Buranaporn, Teerapat Wannawittayapa, Wetch Tantrapongsathorn, Rungsima Wanitphakdeedecha
Journal: Journal of the American Academy of Dermatology (2024)
51122 Impact of Race on Efficacy and Safety of Secukinumab Among Patients With Hidradenitis Suppurativa: A Post-Hoc Analysis of the SUNSHINE and SUNRISE Trials
Authors: Julia Riley, Martina Porter, Ryan Sullivan, Ivette Alarcon, Iryna Lobach, Christine-Elke Ortmann, Angela Llobet Martinez, Tiffany Mayo
Journal: Journal of the American Academy of Dermatology (2024)
52036 Comparative Study on the Effectiveness and Safety of 0.13% CBD Acne Cream with 2.5% Benzoyl Peroxide versus 1% Standardized Clindamycin Gel with 2.5% Benzoyl Peroxide for the Treatment of Acne Vulgaris: A Randomized Controlled Trial
Authors: Sirashat Hanvivattanakul
Journal: Journal of the American Academy of Dermatology (2024)
54519 Advancing Understanding of Keloids and Hypertrophic Scarring: Empowering Communities of Color through Virtual Outreach Events
Authors: Ogechi Ezemma, Kaelynn Workman, Sara Ragi, Samer Wahood, Kelita Waterton, Jasmine Gibson, Michel Ntiri, Idowu Olugbade, Esther Henebeng, Nicole Negbenebor, Uzoamaka Okoro
Journal: Journal of the American Academy of Dermatology (2024)
52990 MRPGRX2 Antagonist EP262 Inhibits Mast Cell Activation and Attenuates Disease in a Mouse Model of Atopic Dermatitis
Authors: Joshua Wollam, Michelle Solomon, Christiane Villescaz, Swetha Srinivasan, Brittney Charlot, Alan Vest, Jim Napora, Christine Cavarlez, Lisa Dvorak, Andres Nevarez, Veena Viswanath
Journal: Journal of the American Academy of Dermatology (2024)
51941 Hidradenitis Suppurativa is Associated with Cardiometabolic Comorbidities After Controlling for Obesity in a Racially/Ethnically Diverse Population: A Cross-Sectional Analysis
Authors: Mariano Alba Anguiano, Nora Rudd, Adam Zakaria, Erin H. Amerson, Aileen Y. Chang
Journal: Journal of the American Academy of Dermatology (2024)
52696 Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in symptom severity assessed using Psoriasis Symptoms and Impacts Measure (P-SIM) thresholds in BE VIVID and BE SURE
Authors: Alice B. Gottlieb, Richard B. Warren, Matthias Augustin, Steven R. Feldman, Andreas Pinter, Julia-Tatjana Maul, Rhys Warham, Jérémy Lambert, Susanne Wiegratz, Georgios Kokolakis
Journal: Journal of the American Academy of Dermatology (2024)
54431 Reduction of eczematous skin lesions and pruritus by topical GZ21T in an atopic dermatitis preclinical model
Authors: Selina Yossef, Weiying Lu, Sriya Reddy, Brenda Umenita Imo, Jaya Manjunath, Alexander Kollhoff, Emily Ma, Cameron West, Shawn Kwatra, Madan Kwatra
Journal: Journal of the American Academy of Dermatology (2024)
51630 Wrinkles in Patient Care: How Do Older Psoriasis Patients Perceive Clinicians’ Delivery of Shared Decision-Making?
Authors: Robin Kikuchi, Paige Kingston, Danielle Yee, Audrey Hao, Rebecca K. Yamamoto, Hannah C. Tolson, Sara N. Bilimoria, Kaviyon Sadrolashrafi, Maria T. Ochoa, April W. Armstrong
Journal: Journal of the American Academy of Dermatology (2024)
52665 The burden of Netherton syndrome and interest in biologics: A qualitative summary of patient and caregiver interview responses
Authors: Amy Paller, Emma Guttman Yassky, Mandy Aldwin-Easton, Karin Veldman, Ana Cristina Hernandez Daly, Suzanne Pasmans, Alain Hovnanian
Journal: Journal of the American Academy of Dermatology (2024)
54168 Maximum-Use Trials of Ruxolitinib Cream in Adults, Adolescents, and Children Aged 2 to &lt;12 Years With Atopic Dermatitis: Consistency of Safety, Pharmacokinetics, and Efficacy
Authors: Robert Bissonnette, Wynnis L. Tom, Daniel Sturm, Brett Angel, Xuejun Chen, Yutzu Kuo, Mark S. Lee
Journal: Journal of the American Academy of Dermatology (2024)
53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: a posthoc analysis of the Phase 2b TREK-AD trial
Authors: Eric Simpson, Melinda Gooderham, Leon Kircik, April W. Armstrong, Todd Schlesinger, James Q. Del Rosso, Dédée F. Murrell, Steven Thng, Jacek C. Szepietowski, Karen A. Veverka, Alexandre Kaoukhov
Journal: Journal of the American Academy of Dermatology (2024)
51618 Reliability, Validity, Responsiveness, and Meaningful Change Thresholds of the Facial–Vitiligo Area Scoring Index (F-VASI) and Total–Vitiligo Area Scoring Index (T-VASI) Among Patients with Non-Segmental Vitiligo
Authors: Iltefat Hamzavi, Ahmed M. Soliman, Heidi S. Camp, Mary Kate Ladd, Robin Pokrzywinski, Rohini Sen, Bethanee J. Schlosser, Jung Min Bae, Khaled Ezzedine
Journal: Journal of the American Academy of Dermatology (2024)
52726 Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I &amp; II
Authors: Falk G. Bechara, Christopher Sayed, Stephanie Goldberg, Jacek C. Szepietowski, Philippe Guillem, Iltefat Hamzavi, Pratiksha Dokhe, Paulatsya Joshi, Robert Rolleri, Leah Davis, Hessel H. van der Zee
Journal: Journal of the American Academy of Dermatology (2024)
53939 Effect of sunscreen containing 7% niacinamide, 0.75% tranexamic acid and 10% of mineral pigments in the skin alterations caused by subsequently exposed to infrared A, visible light and ultraviolet radiations. A ex-vivo study.
Authors: Ana Cláudia Cavalcante Espósito, Priscila Correia, Mariana Feiges, Gustavo Facchini, Erika Fernandes
Journal: Journal of the American Academy of Dermatology (2024)
51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial
Authors: Mark Lebwohl, Michael Bukhalo, Linda Stein-Gold, Michelle Pelle, Bradley Glick, Maria Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Ramon Espaillat, Robert Bissonnette
Journal: Journal of the American Academy of Dermatology (2024)
52351 Treatment of Disseminated Superficial Actinic Porokeratosis with topical cholesterol and statins or statins in monotherapy: a series of 20 patients
Authors: Cristina Barrabés-Torrella, Maribel Iglesias-Sancho, Gemma Melé-Ninot, Joan Ceravalls-Sánchez, Mònica Quintana-Codina, Marina Corral-Forteza, Dídac Marín-Piñero, M Ángeles Sola-Casas, María Blanco De Tord, Jordi Serra-Llobet, Montse Salleras-Redonnet
Journal: Journal of the American Academy of Dermatology (2024)
50250 Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life from the Phase 4 IMMpulse Study
Authors: Andreas Pinter, Linda F. Stein Gold, Jerry Bagel, Stephen Keith Tyring, Ronald Vender, Adam Reich, Lev Pavlovsky, Mark I. Kaldas, Tianshuang Wu, Manish Patel, Kim A. Papp
Journal: Journal of the American Academy of Dermatology (2024)
53808 Adjuvant Pembrolizumab Versus Placebo in Stage IIB or IIC Melanoma: Exploratory Post Hoc Analyses of Patients with New Primary Melanoma and Other Skin Cancers from the Phase 3 KEYNOTE-716 Study
Authors: Sancy Leachman, Jason J. Luke, Paolo Ascierto, Georgina V. Long, Muhammad A. Khattak, Piotr Rutkowski, Zhi Jin Xu, Mizuho Fukunaga-Kalabis, Clemens Krepler
Journal: Journal of the American Academy of Dermatology (2024)
52794 The K-opioid Receptor Agonists in the Treatment of Pruritus in Hemodialysis Patients: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Marcos Freitas, Marina Burla, Larissa Hespanhol, Caroline Balieiro, Sabrina Wantowski, Patricia Coutinho, Lilia Maria Lima de Oliveira
Journal: Journal of the American Academy of Dermatology (2024)
53557 Pumping Up Dermatologic Drug Reformulation: A Novel Phase II/III Clinical Trial of Topically Reformulated Proton-Pump-Inhibitor Esomeprazole for Prevention and Treatment of Radiation Dermatitis in Breast Cancer
Authors: Aaron Cheng, Pavela Bambekova, Joshua Owen, Yohannes Ghebre, Mark Bonnen, Timothy Wagner, Shraddha Dalwadi
Journal: Journal of the American Academy of Dermatology (2024)
53693 Dupilumab Improves Emotional Burden in Patients with Chronic Spontaneous Urticaria Uncontrolled by H1 Antihistamines
Authors: Ana Maria Gimenez-Arnau, Lisa A. Beck, Marcus Maurer, Shunsuke Takahagi, Luis Felipe Ensina, Philip Sugerman, Jerome Msihid, Sonya Cyr, Ryan B. Thomas, Chien-Chia Chuang
Journal: Journal of the American Academy of Dermatology (2024)